Yipinhong Subsidiary Commissions Boji Medical to Conduct Clinical Study for Innovative Drug, Contract Value 6.5 Million Yuan

财中社··Read original
2▲2 ▼0Impact / 5
Summary · why it matters

Yipinhong's wholly owned subsidiary, Yipinhong Pharmaceutical, plans to sign a technical service contract with Boji Medical, commissioning it to conduct a clinical study for the innovative drug APH04935 tablets. The total contract value is 6.5 million yuan, tax inclusive. This transaction constitutes a related-party transaction because Yipinhong's independent director Zhang Kejian also serves as a non-independent director of Boji Medical. In the first quarter of 2026, Yipinhong achieved revenue of 385 million yuan and net profit attributable to the parent company of 594 million yuan.

Impact on assets 2

Others▲